Cabaletta Bio Inc (CABA)
12.34
-0.28
(-2.22%)
USD |
NASDAQ |
May 17, 16:00
12.67
+0.33
(+2.67%)
After-Hours: 20:00
Cabaletta Bio Free Cash Flow (Quarterly): -24.80M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -24.80M |
| December 31, 2023 | -16.63M |
| September 30, 2023 | -12.67M |
| June 30, 2023 | -11.95M |
| March 31, 2023 | -12.99M |
| December 31, 2022 | -12.45M |
| September 30, 2022 | -11.01M |
| June 30, 2022 | -12.42M |
| March 31, 2022 | -12.96M |
| December 31, 2021 | -10.67M |
| September 30, 2021 | -8.874M |
| Date | Value |
|---|---|
| June 30, 2021 | -6.968M |
| March 31, 2021 | -8.767M |
| December 31, 2020 | -9.40M |
| September 30, 2020 | -5.186M |
| June 30, 2020 | -7.662M |
| March 31, 2020 | -5.157M |
| December 31, 2019 | -8.156M |
| September 30, 2019 | -2.116M |
| June 30, 2019 | -4.021M |
| March 31, 2019 | -2.445M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-24.80M
Minimum
Mar 2024
-2.116M
Maximum
Sep 2019
-10.24M
Average
-10.03M
Median
Free Cash Flow (Quarterly) Benchmarks
| Editas Medicine Inc | -51.74M |
| ACADIA Pharmaceuticals Inc | 29.08M |
| Alnylam Pharmaceuticals Inc | -94.49M |
| Regeneron Pharmaceuticals Inc | 1.351B |
| Vertex Pharmaceuticals Inc | 1.058B |